Drugs / LAVA-1207
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05369000 | Jan 2022 → Jun 2025 | castration-resistant prostate carcinoma | Lava Therapeutics | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAVA-1207 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05369000 ↗ |
| Modality | Other / unclassified | “LAVA-1207, a PSMA-targeting Bispecific γδ-T Cell Engager” NCT05369000 ↗ |
| Route | Intravenous | “LAVA-1207 will be administered via intravenous infusion.” NCT05369000 ↗ |